Cosmo Pharmaceuticals announces preliminary end result of its tender offer for BioXell
BioXell S.p.A. announced that, on 26 February 2010, which is the end of the additional acceptance period, Cosmo Pharmaceuticals S.p.A. holds 98.96 percent of the shares, respectively voting rights of BioXell S.p.A, Milano.
Until the end of the additional acceptance period on 26 February 2010, 5,325,713 shares of BioXell with a par value of EUR 5 each ("BioXell Shares") have been tendered under the public tender offer of 8 December 2009 made to the shareholders of BioXell ("Offer"). This corresponds to 98.96 percent of all BioXell Shares, respectively of all shares, which the Offer refers to. Aside from the BioXell Shares tendered under the Offer, Cosmo did not acquire any BioXell Shares or any other equity securities. Thus, as of the end of the additional acceptance period and subject to the execution of the Offer, Cosmo (including the persons acting in concert with Cosmo) holds a total of 5,325,713 BioXell Shares corresponding to 98.96 percent of the shares respectively voting rights of BioXell.
This result is provisional and is subject to the final evaluation of the declarations of acceptance of the shareholders of BioXell. Cosmo will publish the final end result on 4 March 2010.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
